San Jose, Calif. – Feb. 18, 2014 –Two studies presented at the American Society of Spine Radiology (ASSR) 2014 Annual Symposium in Miami highlighted the benefits of Targeted Radiofrequency Ablation™ (t-RFA) therapy with the DFINE STAR™ Tumor Ablation System. The studies demonstrated the ability of the STAR System to provide significant pain relief to patients suffering from painful spinal metatases; in many cases, these patients had not responded to standard therapies, such as radiation or chemotherapy. The first study, conducted by Bassem Georgy, M.D., Assistant Clinical Professor of Radiology at the University of California, San Diego, noted improvement in pain and functional status (quality of life) in all patients. The study also concluded that the targeted and minimally invasive nature of the STAR System allowed treatment of all of the studied tumors regardless of their location. The second study, conducted by Jack Jennings, M.D., PhD, Director of Musculoskeletal and Spine Interventions at the Mallinckrodt Institute of Radiology in St. Louis, demonstrated the value of the STAR System in treating patients who were not responsive to other standard treatments and who had tumors very close to the spinal cord (posterior lesions). In addition to relieving pain, the study concluded that the STAR System had successfully destroyed the lesions, and that in many patients no regrowth was observed during the study period.< “We are pleased with the continued success of STAR in providing pain relief to the many cancer patients suffering from spinal tumors,” said Greg Barrett, Chief Executive Officer of DFINE. “The therapy continues to gain momentum and we are gratified to see more clinicians embracing the technology to help their patients.” About STAR™ Tumor Ablation System The STAR Tumor Ablation System does not treat cancer. It was cleared by the FDA in 2010 for providing palliative treatment (e.g., pain relief) by ablation of metastatic malignant tumors in a vertebral body. With its use of targeted radiofrequency (RF) energy, the STAR System enables physicians to achieve pain relief through the use of a single, minimally invasive procedure that may be compatible with both chemo and radiation therapy. As with all surgical procedures, there are risks and contraindications associated with the STAR System which are described in the product labeling. The STAR System is available at more than 200 institutions in the U.S. For more information regarding spinal tumors or to find a physician, visit http://www.spine-tumors.com. About STAR™ Tumor Ablation System t-RFA with the STAR System does not treat cancer. It is cleared by the FDA for providing palliative treatment (e.g. pain relief) by ablation of metastatic malignant tumors in a vertebral body. For a complete list of indications, risks and contraindications, visit http://www.dfineinc.com/Product-Risk—SpineSTAR About DFINE, Inc.DFINE is dedicated to relieving pain and improving the quality of life for patients suffering from spinal diseases through innovative, minimally invasive therapies. The company’s flagship products, the StabiliT® Vertebral Augmentation System and STAR™ Tumor Ablation System, represent generational advancements in the minimally invasive treatment of spinal diseases. DFINE is based in San Jose, Calif. and is a privately held company. DFINE and StabiliT are registered trademarks and STAR and Targeted Radiofrequency Ablation (t-RFA) are trademarks of DFINE, Inc. Media Contact Susan Benton Russell T: [email protected]
©2018 Merit Medical Systems.
All rights reserved.
1600 West Merit Parkway South Jordan UT 84095 USA
+1 801 253 1600
+1 801 253 1652